OTLC
Oncotelic Therapeutics, Inc.·Healthcare
0.03
25.000%(−0.01)
Close PriceLast Updated: — ET
52W L: $0.0252W H: $0.11
OTLC NEWS
globenewswire.com
6d ago
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
globenewswire.com
Apr 8
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Operates at Intersection of Life Sciences, Advanced Digital Technologies,
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by AINewsWire ("AINW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
globenewswire.com
Mar 24
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company.
globenewswire.com
Mar 23
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration–driven effects, at the upcoming Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo, taking place March 22–25, 2026, in San Diego, California.
defenseworld.net
Mar 15
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Profitability This table compares Oncotelic Therapeutics and
globenewswire.com
Feb 23
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit https://nnw.fm/hsKrq To read the original editorial, visit https://nnw.fm/IA5ih Platforms supported by existing human data also carry valuation advantages.
